英賽德藥學
(INCY)

  • 股價
    58.82
  • 漲跌
    0.86
  • 漲幅
    1.48%
  • 成交量
    10.3萬
YahooFinanceBusiness
Total FY'23 Net Revenues: $3.7 billion, a 14% increase year-over-year.
Jakafi Net Revenues: $2.6 billion for FY'23, an 8% increase year-over-year.
Opzelura Cream Net Revenues: $109 million in Q4'23, contributing to $338 million for FY'23.
Research and Development: Advancing pipeline with potenti
    YahooFinanceBusiness
    (Bloomberg) -- Novartis AG agreed to buy MorphoSys AG for €2.7 billion ($2.9 billion) as the Swiss pharma company starts following through on plans to use bolt-on acquisitions to beef up its pipeline.
    Most Read from Bloomberg
    King Charles Treated for Cancer in New Health Scare for Monarchy
    Why N
      YahooFinanceBusiness
      Delaware has its own drug.
      Specifically, the First State may be the first state in the nation to have a generic drug named after it, said Incyte CEO Hervé Hoppenot in his keynote address at the annual dinner for the Delaware State Chamber of Commerce on Monday.
      To a mix of surprise and applause, 
        YahooFinanceBusiness
        One of the most contentious public fights in New Castle County politics is likely over ... at least, for the moment.
        Councilman David Tackett announced Thursday afternoon that without further public debate, he plans to withdraw a controversial comprehensive rezoning ordinance, 23-083, from public 
          YahooFinanceBusiness
          In a recent transaction filed with the SEC, Steven Stein, EVP & Chief Medical Officer of Incyte Corp (NASDAQ:INCY), sold 7,365 shares of the company on January 3, 2024. The transaction was disclosed in a SEC Filing.
          Warning! GuruFocus has detected 3 Warning Sign with INCY.
          Incyte Corp is a biopha
            YahooFinanceBusiness
            In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising Gene Editing Stocks. 
            
              YahooFinanceBusiness
              In this piece, we will take a look at the 12 biggest healthcare stocks in Jim Simons' stock portfolio. If you want to skip our introduction to the billionaire former hedge fund boss and the healthcare industry, then read Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks. 
              Owing to the sheer